API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/10/30/2768968/0/en/ArriVent-Receives-FDA-Breakthrough-Therapy-Designation-for-Furmonertinib-for-First-Line-Treatment-of-Advanced-or-Metastatic-Non-Small-Cell-Lung-Cancer-with-EGFR-Exon-20-Insertion-M.html